Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 13,959 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: combined treatment Clear all
Completed Phase 1 Interventional

Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00390403
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
R-(-)-gossypol acetic acid, temozolomide, gene expression analysis, mutation analysis, protein expression analysis, laboratory biomarker analysis, pharmacological study, adjuvant therapy, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
8
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 15, 2026, 1:05 AM EDT
Recruiting Phase 2 Interventional

Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

NCT06732388
View directory record Official record
Conditions
Barrett Esophagus, Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Esophageal Adenocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Endoscopic Procedure, Itraconazole, Placebo Administration, Questionnaire Administration, Radiofrequency Ablation
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Kansas City, Kansas • Ann Arbor, Michigan • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 15, 2026, 1:05 AM EDT
Completed Phase 3 Interventional Results available

Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease

NCT04380142
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
ABBV-951, Placebo for Levodopa/Carbidopa (LD/CD), Levodopa/Carbidopa (LD/CD), Placebo for ABBV-951
Drug
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
70
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2022 · Synced Oct 15, 2026, 1:05 AM EDT
Completed Phase 2 Interventional

Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer

NCT00096070
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions
radiation therapy, oxaliplatin, fluorouracil, gemcitabine hydrochloride
Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Oct 15, 2026, 1:05 AM EDT
Terminated Phase 2 Interventional Results available

Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer

NCT00216086
View directory record Official record
Conditions
Rectal Cancer
Interventions
Capecitabine, Irinotecan, EUS, Neoadjuvant Chemotherapy, Preoperative Radiation, Surgery, Adjuvant Chemotherapy
Drug · Procedure
Lead sponsor
Gabi Chiorean, MD
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
9
States / cities
Elkhart, Indiana • Fort Wayne, Indiana • Goshen, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Oct 15, 2026, 1:05 AM EDT
Completed Phase 2 Interventional Results available

Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer

NCT04828486
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Interventions
Futibatinib, Pembrolizumab, Quality-of-Life Assessment
Drug · Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 15, 2026, 1:05 AM EDT
Recruiting Phase 2 Interventional

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

NCT04998669
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Loncastuximab tesirine, Rituximab
Drug
Lead sponsor
Juan P. Alderuccio, MD
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
5
States / cities
Fort Myers, Florida • Miami, Florida • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 15, 2026, 1:05 AM EDT
Terminated Phase 2 Interventional Results available

Multicenter Evaluation of Docetaxel, Gemcitabine, and Bevacizumab Combination Followed by Bevacizumab Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT00378573
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
docetaxel, gemcitabine, bevacizumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 26, 2010 · Synced Oct 15, 2026, 1:05 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Platelet-rich Plasma (PRP) for Endometrial Regeneration and Repair

NCT02825849
View directory record Official record
Conditions
Infertility, Asherman's Syndrome
Interventions
Intrauterine infusion of platelet rich plasma
Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 43 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Oct 15, 2026, 1:05 AM EDT
Completed Phase 1 Interventional

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

NCT05759949
View directory record Official record
Conditions
PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Hormone Receptor Positive Tumor
Interventions
RLY-5836, Fulvestrant, Palbociclib, Ribociclib, Abemaciclib
Drug
Lead sponsor
Relay Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Orlando, Florida • Indianapolis, Indiana • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 15, 2026, 1:05 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies

NCT01998035
View directory record Official record
Conditions
Lymphoid Malignancies, Lymphoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
Interventions
RomiDEPsin 10 MG/M2, Oral 5-Azacitidine 100 MG, Romidepsin 14 MG/M2, Oral 5-Azacitidine 200 MG, Oral 5-Azacitidine 300 MG
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 15, 2026, 1:05 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

NCT03022825
View directory record Official record
Conditions
Bladder Cancer
Interventions
N-803 and BCG, N-803
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
28
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 15, 2026, 1:05 AM EDT
Enrolling by invitation Phase 4 Interventional

Comparing Treatment of Knee Osteoarthritis With Triamcinolone Injections Using 40mg With Landmark Guidance and 20mg With Ultrasound Guidance

NCT07544576
View directory record Official record
Conditions
Knee Arthritis Osteoarthritis
Interventions
Triamcinolone knee injection without ultrasound guidance, Triamcinolone knee injection with ultrasound guidance
Drug · Combination Product
Lead sponsor
Sosi Dzhugarian
Other
Eligibility
50 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 15, 2026, 1:05 AM EDT
Recruiting Phase 2 Interventional

Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer

NCT06576115
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
Nab paclitaxel, Gemcitabine, TheraBionic P1
Drug · Device
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Clarkston, Michigan • Detroit, Michigan • Flint, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 15, 2026, 1:05 AM EDT
Completed Phase 1 Interventional

ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer

NCT02632071
View directory record Official record
Conditions
Metastatic Breast Cancer, Breast Carcinoma
Interventions
ACY-1215, Nab-paclitaxel
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 15, 2026, 1:05 AM EDT
Completed Phase 1 Interventional

A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.

NCT05155709
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
siremadlin, venetoclax, azacitidine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Portland, Oregon • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 15, 2026, 1:05 AM EDT
Withdrawn Phase 2 Interventional

RCT of a Neuroplasticity Agent and CI Therapy for Severe Arm Paresis After Stroke

NCT01963832
View directory record Official record
Conditions
Severe Stroke With Affected Arm Motor Function
Interventions
Fluoxetine, Placebo, eCMIT, Usual Care
Drug · Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 12, 2015 · Synced Oct 15, 2026, 1:05 AM EDT
Active, not recruiting Phase 2 Interventional

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

NCT03175432
View directory record Official record
Conditions
BRAF V600 Wild Type, Clinical Stage IV Cutaneous Melanoma AJCC v8, Intracranial Melanoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Refractory Melanoma
Interventions
Atezolizumab, Bevacizumab, Cobimetinib, Quality-of-Life Assessment
Drug · Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 15, 2026, 1:05 AM EDT
Completed Phase 4 Interventional Results available

Photodynamic Therapy (PDT) With Levulan and Blue Light for the Treatment of Actinic Cheilitis

NCT02409732
View directory record Official record
Conditions
Actinic Cheilitis
Interventions
aminolevulinic acid hydrochloride, Photodynamic therapy with blue light
Drug · Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 15, 2026, 1:05 AM EDT
Recruiting Not applicable Interventional

Stuttering and Neuromodulation

NCT07222163
View directory record Official record
Conditions
Stuttering
Interventions
Soterix Medical 1x1 tDCS system, Speech therapy sessions
Device · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 15, 2026, 1:05 AM EDT
Completed Phase 2 Interventional

A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma

NCT00081614
View directory record Official record
Conditions
Renal Cell Carcinoma, Metastases
Interventions
Avastin (bevacizumab), Tarceva (erlotinib HCl)
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
20
States / cities
Concord, California • Los Angeles, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 15, 2026, 1:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects

NCT02509104
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
FDC capsule of dutasteride and tamsulosin, Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 15, 2026, 1:05 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

NCT02817633
View directory record Official record
Conditions
Neoplasms
Interventions
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
64
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Tucson, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 15, 2026, 1:05 AM EDT
Completed Phase 2 Interventional

A Study of a Combination of Four Drugs in Patients With Recent HIV Infection

NCT00002233
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Amprenavir, Lamivudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
15 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
New York, New York • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 1:05 AM EDT